Biogen (BIIB) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Biogen Revenue Highlights


Latest Revenue (Y)

$9.84B

Latest Revenue (Q)

$2.47B

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Biogen Revenue by Period


Biogen Revenue by Year

DateRevenueChange
2023-12-31$9.84B-3.32%
2022-12-31$10.17B-7.36%
2021-12-31$10.98B-18.32%
2020-12-31$13.44B-6.49%
2019-12-31$14.38B6.88%
2018-12-31$13.45B9.61%
2017-12-31$12.27B7.21%
2016-12-31$11.45B6.36%
2015-12-31$10.76B10.93%
2014-12-31$9.70B39.97%
2013-12-31$6.93B25.66%
2012-12-31$5.52B9.27%
2011-12-31$5.05B7.04%
2010-12-31$4.72B7.75%
2009-12-31$4.38B6.83%
2008-12-31$4.10B29.19%
2007-12-31$3.17B69.41%
2006-12-31$1.87B9.25%
2005-12-31$1.71B7.38%
2004-12-31$1.60B134.96%
2003-12-31$679.18M-40.86%
2002-12-31$1.15B10.06%
2001-12-31$1.04B12.62%
2000-12-31$926.45M16.62%
1999-12-31$794.43M42.48%
1998-12-31$557.59M28.46%
1997-12-31$434.04M56.64%
1996-12-31$277.09M82.67%
1995-12-31$151.69M-2.98%
1994-12-31$156.34M14.62%
1993-12-31$136.40M-

Biogen generated $9.84B in revenue during NA 2023, up -3.32% compared to the previous quarter, and up 73.11% compared to the same period a year ago.

Biogen Revenue by Quarter

DateRevenueChange
2024-09-30$2.47B4.79%
2024-06-30$2.35B6.94%
2024-03-31$2.20B-7.79%
2023-12-31$2.39B-5.69%
2023-09-30$2.53B3.03%
2023-06-30$2.46B-0.28%
2023-03-31$2.46B-3.18%
2022-12-31$2.54B1.42%
2022-09-30$2.51B-3.11%
2022-06-30$2.59B2.26%
2022-03-31$2.53B-7.39%
2021-12-31$2.73B-1.62%
2021-09-30$2.78B0.14%
2021-06-30$2.77B3.01%
2021-03-31$2.69B-5.56%
2020-12-31$2.85B-15.51%
2020-09-30$3.38B-8.30%
2020-06-30$3.68B4.17%
2020-03-31$3.53B-3.73%
2019-12-31$3.67B1.98%
2019-09-30$3.60B-0.46%
2019-06-30$3.62B3.64%
2019-03-31$3.49B-1.04%
2018-12-31$3.53B2.54%
2018-09-30$3.44B2.46%
2018-06-30$3.36B7.20%
2018-03-31$3.13B-5.32%
2017-12-31$3.31B7.45%
2017-09-30$3.08B-0.02%
2017-06-30$3.08B9.52%
2017-03-31$2.81B-2.13%
2016-12-31$2.87B-2.84%
2016-09-30$2.96B2.13%
2016-06-30$2.89B6.14%
2016-03-31$2.73B-3.96%
2015-12-31$2.84B2.21%
2015-09-30$2.78B7.19%
2015-06-30$2.59B1.44%
2015-03-31$2.55B-3.25%
2014-12-31$2.64B5.15%
2014-09-30$2.51B3.72%
2014-06-30$2.42B13.70%
2014-03-31$2.13B8.34%
2013-12-31$1.97B7.55%
2013-09-30$1.83B6.05%
2013-06-30$1.72B21.79%
2013-03-31$1.42B-37.80%
2012-12-31$2.27B107.23%
2012-09-30$1.10B-22.74%
2012-06-30$1.42B9.98%
2012-03-31$1.29B-2.62%
2011-12-31$1.33B1.28%
2011-09-30$1.31B8.38%
2011-06-30$1.21B0.44%
2011-03-31$1.20B-1.29%
2010-12-31$1.22B3.68%
2010-09-30$1.18B-3.04%
2010-06-30$1.21B9.36%
2010-03-31$1.11B-1.61%
2009-12-31$1.13B0.58%
2009-09-30$1.12B2.49%
2009-06-30$1.09B5.48%
2009-03-31$1.04B-3.03%
2008-12-31$1.07B-2.20%
2008-09-30$1.09B10.02%
2008-06-30$993.44M5.44%
2008-03-31$942.19M5.47%
2007-12-31$893.30M-

Biogen generated $2.47B in revenue during Q3 2024, up 4.79% compared to the previous quarter, and up 100.40% compared to the same period a year ago.

Biogen Revenue Breakdown


Biogen Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22Dec 21Dec 20Dec 19Dec 18
TYSABRI product$2.03B----
Interferon$1.31B----
Fumarate$2.00B----
MS Product Revenues$5.43B----
Royalty$67.40M$27.90M$33.90M$17.00M$38.70M
Product and Service, Other$485.10M$18.20M$48.60M$383.20M-
Product$7.99B----
Revenues from anti-cd20 therapeutic programs$1.70B----
SPINRAZA$1.79B----
Other corporate revenues-$427.70M$719.10M$584.50M$459.40M

Biogen's latest annual revenue breakdown by segment (product or service), as of Dec 22: Product (35.04%), MS Product Revenues (23.82%), TYSABRI product (8.91%), Fumarate (8.76%), SPINRAZA (7.87%), Revenues from anti-cd20 therapeutic programs (7.46%), Interferon (5.73%), Product and Service, Other (2.13%), and Royalty (0.30%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
SPINRAZA$381.40M$429.10M$341.30M-----------------
TYSABRI product$406.10M$462.20M$431.30M-----------------
MS Product Revenues$1.05B$1.15B$1.08B-----------------
Interferon$237.50M$250.90M$243.60M-----------------
Fumarate$390.90M$418.00M$381.80M-----------------
Revenues from anti-cd20 therapeutic programs--$394.00M$433.40M$399.50M$447.90M$416.90M$436.30M$399.40M$414.10M$415.40M$440.00M$389.00M$419.00M$560.10M$478.30M$520.40M$600.80M$595.80M$576.40M
Product--$1.71B-----------------
Product and Service, Other--$184.60M$197.50M$319.10M$191.60M$129.50M$97.90M$66.10M$126.20M$157.80M$99.00M$93.30M$132.00M$125.70M$407.60M$109.30M$145.70M$109.60M$160.00M
Royalty---$14.40M$12.20M$8.80M$10.30M$7.60M$7.70M$6.40M$6.20M$5.10M$10.30M$7.10M$11.40M$7.10M$3.30M$2.70M--
Other corporate revenues------$114.20M$81.20M$113.60M$143.80M$87.10M$83.20M$119.60M$110.00M$395.50M$94.00M$122.10M$93.10M$105.20M-

Biogen's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: MS Product Revenues (42.67%), TYSABRI product (16.44%), Fumarate (15.83%), SPINRAZA (15.44%), and Interferon (9.62%).

Biogen Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 22Dec 21Dec 20Dec 19Dec 18
UNITED STATES$3.47B$1.14B$1.10B$5.50M$1.02B
Asia$672.10M----
Europe$2.40B$100.00K$200.00K$200.00K-
Segment Geographical Groups Of Countries Group Other$64.00M$61.80M$80.30M$78.30M$76.60M
GERMANY$926.20M$1.16B---
Europe, Excluding Germany$100.00K----
Non-US-$920.90M$849.30M$850.40M$1.40M

Biogen's latest annual revenue breakdown by geography, as of Dec 22: UNITED STATES (46.05%), Europe (31.88%), GERMANY (12.30%), Asia (8.92%), Segment Geographical Groups Of Countries Group Other (0.85%), and Europe, Excluding Germany (0.00%).

Quarterly Revenue by Country

CountrySep 24Jun 24Mar 24Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Non-US$956.40M$1.05B$965.80M$15.90M$14.70M$12.50M$9.90M$6.90M$236.30M$224.70M$241.70M$224.40M$230.00M$204.40M$212.30M$187.90M$244.70M$203.40M$220.60M$211.00M
UNITED STATES$813.00M$846.70M$746.10M$130.30M$93.50M$138.30M$127.90M$129.90M$284.50M$288.00M$281.10M$299.80M$273.30M$270.80M$304.20M$244.10M$277.70M$269.50M$263.00M$264.30M

Biogen's latest quarterly revenue breakdown by geography, as of Sep 24: Non-US (54.05%), and UNITED STATES (45.95%).

Biogen Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
JNJJohnson & Johnson$85.15B$22.47B
MRKMerck$60.12B$16.11B
PFEPfizer$58.50B$13.28B
ABBVAbbVie$54.32B$14.46B
NVSNovartis$46.66B$11.83B
BMYBristol-Myers Squibb Company$45.01B$11.89B
SNYSanofi$43.07B$11.12B
GSKGSK$30.33B$7.36B
AMGNAmgen$28.19B$8.50B
GILDGilead Sciences$27.12B$6.95B
BIIBBiogen$9.84B$2.47B

BIIB Revenue FAQ


Biogen's yearly revenue for 2023 was $9.84B, representing a decrease of -3.32% compared to 2022. The company's yearly revenue for 2022 was $10.17B, representing a decrease of -7.36% compared to 2021. BIIB's yearly revenue for 2021 was $10.98B, representing a decrease of -18.32% compared to 2020.

Biogen's quarterly revenue for Q3 2024 was $2.47B, a 4.79% increase from the previous quarter (Q2 2024), and a -2.55% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $2.35B, a 6.94% increase from the previous quarter (Q1 2024), and a -4.19% decrease year-over-year (Q2 2023). BIIB's quarterly revenue for Q1 2024 was $2.2B, a -7.79% decrease from the previous quarter (Q4 2023), and a -10.67% decrease year-over-year (Q1 2023).

Biogen's revenue growth rate for the last 3 years (2021-2023) was -10.44%, and for the last 5 years (2019-2023) was -31.59%.

Biogen's revenue streams in c 22 are TYSABRI product, Interferon, Fumarate, MS Product Revenues, Royalty, Product and Service, Other, Product, Revenues from anti-cd20 therapeutic programs, and SPINRAZA. TYSABRI product generated $2.03B in revenue, accounting 8.91% of the company's total revenue Interferon generated $1.31B in revenue, accounting 5.73% of the company's total revenue Fumarate generated $2B in revenue, accounting 8.76% of the company's total revenue MS Product Revenues generated $5.43B in revenue, accounting 23.82% of the company's total revenue Royalty generated $67.4M in revenue, accounting 0.30% of the company's total revenue, up 141.58% year-over-year. Product and Service, Other generated $485.1M in revenue, accounting 2.13% of the company's total revenue, up 2565.38% year-over-year. Product generated $7.99B in revenue, accounting 35.04% of the company's total revenue Revenues from anti-cd20 therapeutic programs generated $1.7B in revenue, accounting 7.46% of the company's total revenue SPINRAZA generated $1.79B in revenue, accounting 7.87% of the company's total revenue

For the fiscal year ending Dec 22, the largest source of revenue of Biogen was Product. This segment made a revenue of $7.99B, representing 35.04% of the company's total revenue.